Retatrutide Pen 20mg – Pre-Filled 3mL Cartridge

Retatrutide Pen 20mg  is a pre-filled 3mL cartridge format containing retatrutide, an investigational peptide being studied for its activity across three hormone receptors: GIP, GLP-1, and glucagon.

Retatrutide has become an important subject of metabolic research because of its distinctive triple-receptor mechanism. Clinical research programs are evaluating the compound across obesity, type 2 diabetes, cardiovascular and metabolic conditions, and other areas of interest.

Important: Retatrutide is investigational and is not currently FDA-approved for public use. It should not be represented as an approved treatment or medication. The information on this page is provided for educational and research-information purposes only.

Retatrutide Pen 20mg Product Information

The Retatrutide Pen 20mg  is presented in a pre-filled 3mL cartridge format.

Product specifications

• Compound: Retatrutide
• Labeled amount: 20mg
• Format: Pre-filled 3mL cartridge
• Product category: Investigational research compound
• Research area: Metabolic and receptor-signaling research
• Receptor activity: GIP, GLP-1, and glucagon
• Intended context: Research and educational purposes

Product documentation and labeling should always be reviewed before any laboratory research involving an investigational compound.

What Is Retatrutide?

Retatrutide is an investigational peptide developed as a triple hormone receptor agonist. Unlike medicines that primarily target one or two incretin-related pathways, retatrutide is designed to activate receptors associated with GIP, GLP-1, and glucagon.

According to its developer, Eli Lilly, retatrutide is being investigated in Phase 3 clinical programs. Current research includes obesity, type 2 diabetes, cardiovascular outcomes, obstructive sleep apnea, knee osteoarthritis pain, chronic low back pain, kidney-related outcomes, and metabolic dysfunction-associated steatotic liver disease.

How Retatrutide Works in Research

Retatrutide’s research interest comes primarily from its combined activity at three hormone receptors.

GIP Receptor Activity

Glucose-dependent insulinotropic polypeptide, commonly abbreviated as GIP, is a hormone involved in metabolic signaling and glucose regulation.

Research into GIP receptor activity helps scientists understand how this pathway may interact with other metabolic signaling systems.

GLP-1 Receptor Activity

Glucagon-like peptide-1, or GLP-1, is another hormone involved in glucose and metabolic regulation.

GLP-1 receptor signaling has been extensively studied in metabolic research, providing an important foundation for investigating compounds that interact with this pathway.

Glucagon Receptor Activity

Glucagon is involved in energy metabolism and glucose regulation.

Retatrutide’s additional glucagon receptor activity distinguishes it from compounds that primarily target GLP-1 or GLP-1 and GIP pathways.

The simultaneous activity across these three receptors is why retatrutide is commonly described as a triple agonist.

Why Is Retatrutide Being Studied?

Researchers are interested in retatrutide because its multi-receptor mechanism may provide a different approach to studying metabolic regulation.

Clinical research has examined areas including:

• Body-weight regulation
• Glucose metabolism
• Energy metabolism
• Cardiometabolic health
• Obesity-related complications
• Type 2 diabetes
• Obstructive sleep apnea
• Knee osteoarthritis
• Cardiovascular outcomes
• Renal and metabolic conditions

These areas remain subjects of clinical investigation and should not be interpreted as established indications for an approved retatrutide product.

Retatrutide Clinical Research

Retatrutide has progressed into Phase 3 clinical development.

In May 2026, Eli Lilly reported results from TRIUMPH-1, a pivotal Phase 3 obesity study. The company reported substantial weight reductions at 80 weeks among study participants receiving retatrutide.

In July 2026, Lilly also reported Phase 3 results from TRIUMPH-2 and TRIUMPH-3, evaluating retatrutide in adults with obesity or overweight alongside type 2 diabetes and established cardiovascular disease, respectively.

These results represent clinical-trial findings and do not mean that retatrutide has received regulatory approval.

Retatrutide Pen 20mg Format

The 20mg designation identifies the labeled amount of retatrutide associated with this product format, while the 3mL designation describes the cartridge volume.

The pre-filled cartridge format provides a defined physical presentation for the material. Researchers should rely on the applicable product documentation for specifications, handling requirements, storage conditions, and other laboratory considerations.

This page does not provide instructions for administering retatrutide to humans.

Retatrutide vs. Other Incretin Research Compounds

Retatrutide is particularly notable because it combines three receptor targets.

Compound	Primary receptor activity	Research distinction
Semaglutide	GLP-1	GLP-1 receptor agonist
Tirzepatide	GIP + GLP-1	Dual receptor agonist
Retatrutide	GIP + GLP-1 + glucagon	Triple receptor agonist

The comparison is based on receptor activity and research mechanism. It should not be interpreted as a comparison of approved treatment options or as a recommendation for human use.

Retatrutide Research Considerations

Investigational compounds require careful attention to identity, labeling, documentation, storage, handling, and applicable regulatory requirements.

Researchers should verify the documentation associated with any material before beginning laboratory work.

Important considerations may include:

• Product identity
• Lot or batch information
• Documentation supplied with the material
• Storage requirements
• Handling procedures
• Laboratory protocols
• Applicable institutional requirements
• Applicable local and federal regulations

Research materials should not be confused with approved pharmaceutical products.

Is Retatrutide FDA Approved?

No. Retatrutide is not currently FDA-approved.

The FDA states that retatrutide has not been found safe and effective for any condition and cannot be used in compounding under federal law. The agency has also warned about products marketed as retatrutide for consumer use.

Eli Lilly describes retatrutide as an investigational medicine and reports that it remains in clinical development.

Frequently Asked Questions About Retatrutide Pen 20mg

What is a Retatrutide Pen 20mg ?

A Retatrutide Pen 20mg  is a pre-filled 3mL cartridge format labeled to contain 20mg of retatrutide. Retatrutide is an investigational triple-receptor agonist being studied for metabolic applications.

What receptors does retatrutide target?

Retatrutide activates three receptor pathways: GIP, GLP-1, and glucagon. This triple-receptor activity is the defining characteristic of the compound.

Is retatrutide approved for weight loss?

No. Retatrutide is not currently FDA-approved for weight loss or any other general public use. It remains under clinical investigation.

What is the difference between retatrutide and tirzepatide?

Retatrutide is being investigated as a triple agonist targeting GIP, GLP-1, and glucagon receptors, while tirzepatide acts on GIP and GLP-1 receptors.

What is the difference between retatrutide and semaglutide?

Semaglutide primarily activates the GLP-1 receptor, while retatrutide is being investigated for activity across GIP, GLP-1, and glucagon receptors.

Is retatrutide available as an approved prescription medication?

No. Retatrutide is still investigational and is not currently approved by the FDA. Lilly states that retatrutide remains in clinical development.

What does 20mg mean on the product?

The 20mg designation refers to the labeled amount of retatrutide associated with the product. The accompanying product documentation should be used for complete specifications.

What does 3mL mean?

The 3mL specification refers to the labeled cartridge volume. It does not by itself establish a dosing schedule or instructions for human administration.

Related Searches

People researching retatrutide may also search for information about:

• Retatrutide Pen 20mg 
• Retatrutide 20mg research peptide
• Retatrutide vs tirzepatide
• Retatrutide vs semaglutide
• How does retatrutide work?
• Retatrutide receptor activity

Research and Regulatory Disclaimer

Retatrutide is an investigational compound and is not currently approved by the FDA for human use.

Nothing on this page should be interpreted as medical advice, prescribing information, treatment guidance, dosing instructions, or a recommendation to use retatrutide in humans.

The information presented is intended to provide general educational information about retatrutide’s research status, receptor activity, and product format. Researchers are responsible for complying with all applicable laws, regulations, institutional requirements, and laboratory safety procedures.

FDA has specifically cautioned against consumer use of products marketed as retatrutide outside approved clinical research and has warned that products sold as research compounds may be of unknown quality.

Retatrutide Research Information

Retatrutide represents an active area of metabolic research because of its unique triple-receptor mechanism. With ongoing Phase 3 development and continued investigation across multiple metabolic conditions, researchers are continuing to evaluate its pharmacological profile, efficacy, and safety.

For the latest information about clinical development and regulatory status, consult current information from relevant regulatory authorities and the compound’s clinical-development sponsor.